Business Description
EQRx Inc
NAICS : 541715
SIC : 2834
50 Hampshire Street, Cambridge, MA, USA, 02139
Description
EQRx Inc is a biotechnology company. Its pipeline programs include two pre-registrational oncology assets that have shown assuring Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 617.45 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.43 | |||||
| 9-Day RSI | 68.02 | |||||
| 14-Day RSI | 62.86 | |||||
| 6-1 Month Momentum % | 33.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 29.23 | |||||
| Quick Ratio | 29.23 | |||||
| Cash Ratio | 28.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | 2.35 | |||||
| ROA % | 1.69 | |||||
| ROIC % | -699.17 | |||||
| ROC (Joel Greenblatt) % | -3922.32 | |||||
| ROCE % | -14.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 138.16 | |||||
| PE Ratio without NRI | 138.16 | |||||
| PB Ratio | 1.79 | |||||
| Price-to-Tangible-Book | 1.81 | |||||
| EV-to-EBIT | -7.06 | |||||
| EV-to-Forward-EBIT | -2.86 | |||||
| EV-to-EBITDA | -7.07 | |||||
| EV-to-Forward-EBITDA | -2.86 | |||||
| EV-to-FCF | -8.7 | |||||
| Price-to-Graham-Number | 3.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.83 | |||||
| Price-to-Net-Cash | 1.87 | |||||
| Earnings Yield (Greenblatt) % | -14.21 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:EQRX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | 0.043 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 62.86 | ||
| 14-Day ATR ($) | 0.408044 | ||
| 20-Day SMA ($) | 5.111 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 2.63 - 8.6999 | ||
| Shares Outstanding (Mil) | 487.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EQRx Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||